Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

被引：27
|
作者：
Javle, Milind M.
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Personeni, Nicola
Adeva, Jorge
Bergamo, Francesca
Malka, David
Vogel, Arndt
Knox, Jennifer J.
Evans, T. R. Jeffry
Dimova-Dobreva, Miryana
Harris, William Proctor
Saulay, Mikael
Engelhardt, Marc
Braun, Stephan
Busset, Michele Droz Dit
Borad, Mitesh J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[4] Hosp Univ Vall dHebron, Barcelona, Spain
[5] Ist Clin Humanitas, Humanitas Canc Ctr, Rozzano, Italy
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Oncol 1, Padua, Italy
[8] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France
[9] Hannover Med Sch, Hannover, Germany
[10] Univ Hlth Network, Wallace McCain Ctr Pancreat Canc, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[12] Basilea Pharmaceut Int Ltd, Basel, NJ, Switzerland
[13] Univ Washington, Seattle Canc Care Alliance SCCA, Seattle, WA 98195 USA
[14] Natl Inst Canc, Dept Hepatopancreatobiliary Surg & Liver Transpla, Milan, Italy
[15] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
427
引用
收藏
页数：3
相关论文
共 50 条
  • [1] FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A)
    Javle, Milind M.
    Shaib, Walid Labib
    Braun, Stephan
    Engelhardt, Marc
    Borad, Mitesh J.
    Abou-Alfa, Ghassan K.
    Boncompagni, Andrea
    Friedmann, Silke
    Gahlemann, Christoph Georg
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements: Primary results from the phase II study FIDES-01
    Busset, M. Droz Dit
    Shaib, W. L.
    Mody, K.
    Personeni, N.
    Damjanov, N.
    Harris, W. P.
    Bergamo, F.
    Brandi, G.
    Masi, G.
    Halfdanarson, T. R.
    Tam, V.
    Goff, L. W.
    Knox, J.
    Hollebecque, A.
    Macarulla Mercade, T.
    Cantero, F.
    Saulay, M.
    Braun, S.
    Javle, M.
    Borad, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S376 - S376
  • [3] Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
    Borad, M.
    Javle, M.
    Shaib, W. L.
    Mody, K.
    Bergamo, F.
    Harris, W. P.
    Damjanov, N.
    Macarulla, T.
    Brandi, G.
    Masi, G.
    Busset, M. Droz Dit
    Boncompagni, A.
    Dimova-Dobreva, M.
    Engelhardt, M.
    Saulay, M.
    Halfdanarson, T. R.
    Knox, J.
    Abou-Alfa, G. K.
    Personeni, N.
    Mazzaferro, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S567 - S568
  • [4] Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
    Busset, M. Droz Dit
    Braun, S.
    El-Rayes, B.
    Harris, W. P.
    Damjanov, N.
    Masi, G.
    Rimassa, L.
    Bhoori, S.
    Niger, M.
    Personeni, N.
    Braiteh, F.
    Lonardi, S.
    Engelhardt, M.
    Saulay, M.
    Schwartz, B.
    Shaib, W. L.
    Mazzaferro, V.
    Papadopoulos, K. P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Pooled analysis of clinical trials and early access programs
    Busset, M. Droz Dit
    Shaib, W. L.
    Harris, W. P.
    Damjanov, N.
    Borad, M.
    Vogel, A.
    Bridgewater, J. A.
    Sellmann, L.
    Dadduzio, V.
    Borner, M.
    Snider, J.
    Cantero, F.
    Saulay, M.
    Braun, S.
    Mazzaferro, V.
    Javle, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1231 - S1231
  • [6] FGFR2 fusion in resectable intrahepatic cholangiocarcinoma patients
    Xu, S.
    Zheng, Y.
    Gong, W.
    Li, B.
    Wang, Y.
    Li, H.
    Zhao, S.
    Shi, X.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S267 - S267
  • [7] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
    Mazzaferro, Vincenzo
    El-Rayes, Bassel F.
    Busset, Michele Droz Dit
    Cotsoglou, Christian
    Harris, William P.
    Damjanov, Nevena
    Masi, Gianluca
    Rimassa, Lorenza
    Personeni, Nicola
    Braiteh, Fadi
    Zagonel, Vittorina
    Papadopoulos, Kyriakos P.
    Hall, Terence
    Wang, Yunxia
    Schwartz, Brian
    Kazakin, Julia
    Bhoori, Sherrie
    de Braud, Filippo
    Shaib, Walid L.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 165 - 171
  • [8] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
    Vincenzo Mazzaferro
    Bassel F. El-Rayes
    Michele Droz dit Busset
    Christian Cotsoglou
    William P. Harris
    Nevena Damjanov
    Gianluca Masi
    Lorenza Rimassa
    Nicola Personeni
    Fadi Braiteh
    Vittorina Zagonel
    Kyriakos P. Papadopoulos
    Terence Hall
    Yunxia Wang
    Brian Schwartz
    Julia Kazakin
    Sherrie Bhoori
    Filippo de Braud
    Walid L. Shaib
    British Journal of Cancer, 2019, 120 : 165 - 171
  • [9] FGFR2 fusion and/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma
    Huang, X-W.
    Shi, G-M.
    Zhang, T.
    Bao, L-Q.
    Wen, T-F.
    Zhang, B.
    Peng, T.
    Zhao, H.
    Kuang, M.
    Wang, W-L.
    Ran, J-H.
    Liu, Y-B.
    Gong, W.
    Mou, H-B.
    Luo, Y.
    Wang, Y.
    Sun, H.
    Fan, J.
    Liu, L-X.
    Dai, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S379 - S379
  • [10] Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
    Calfa, Carmen J.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Ahn, Eugene R.
    Burness, Monika L.
    Gogineni, Keerthi
    Rohatgi, Nitin
    Al Baghdadi, Tareq
    Conlin, Alison
    Gaba, Anu
    Hamid, Omid
    Krishnamurthy, Jairam
    Gavini, Naga Jyothi
    Gold, Philip J.
    Rodon, Jordi
    Rueter, Jens
    Thota, Ramya
    Grantham, Gina N.
    Hinshaw, Dominique C.
    Gregory, Abigail
    Halabi, Susan
    Schilsky, Richard L.
    JCO PRECISION ONCOLOGY, 2024, 8
12345